ABNOM
☆ AI Dermatology — Free Service
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
relevance score : -100.0%
ReferencesLaser Q‑switched Nd:YAG notus est ad efficacem tractationem nevus de Ota et conditionum similium. Studium perduximus ad cognoscendum quam bene laser high‑fluence 1064 nm Q‑switched Nd:YAG in locis inusitatis Mongolicae laboravit, quin cutem levaret. Studium includit 61 aegros, cum totalibus 70 laesionibus examinatis. Dimidium laesionum cum laser tractatum est, aliae ad comparationem non tractatae relictae. Eventus aestimavimus utens instrumentum Mexameter® ad mensuram gradus melaninarum. Aegros quattuor mensibus in curatione coetus et XVIII mensibus in coetu observationis secuti sunt. In fine studii invenimus notabiles differentias in gradibus ustulo et melanini inter circulos tractatos et non tractatos, cum coetus laser‑tractatus meliores eventus ostendit. Laser high‑fluence Q‑switched Nd:YAG, sine levatione cutis, probatus est efficax et tutus ad has maculas Mongolicas insolitas tractandas.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Studebamus efficaciam et salutem usus laseris specifici pro ABNOM, et spectavimus quae causae afficerent quam bene operaretur. Inspeximus 110 aegros qui ABNOM habebant et inter duas curationes laseris novem comparavimus. Curatio melior facta diutius invenitur, sed non tam in vetustioribus aegrotibus. Etiam melius in aegrotibus cum cutibus levioribus laboravit (species III) et in locis affectis minoribus (minus quam 10 cm²). Cum melasma una cum ABNOM curationem minus efficacem fecit. Color vel numerus arearum affectarum differentiam facere non videtur. Circa 10 % aegrotorum post curationem maculas obscuriores obtinuit. Mane multa curatio bonos eventus dedit. In antiquioribus aegrotis cum cutis obscuriore et macula obscura sunt, magis verisimile est post curationem maculas obscuriores accipere. In aegrotis cum ABNOM et melasma, satius est laser energia inferiore uti ne melasma peius fiat.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Curatio
Candidatio agentium raro adiuvat. Diversum a melasma, ABNOM cum laseris curatione emendari potest et sine recursu relinquitur. Curatio laseris potest perfici per 10‑20 sessiones ad tractandum ABNOM.
#QS1064 laser